Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin

We conducted a trial of a murine monoclonal antimelanoma antibody-ricin A chain immunotoxin (XOMAZYME-MEL) in 22 patients with metastatic malignant melanoma. The dose of immunotoxin administered ranged from 0.01 mg/kg daily for 5 days to 1 mg/kg daily for 4 days (total dose: 3.2 to 300 mg). Side eff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1987-03, Vol.47 (6), p.1717-1723
Hauptverfasser:	SPITLER, L. E, DEL RIO, M, KAWAHATA, R. T, STOUDEMIRE, J. B, FRADKIN, L. B, BAUTISTA, E. E, SCANNON, P. J, KHENTIGAN, A, WEDEL, N. I, BROPHY, N. A, MILLER, L. L, HARKONEN, W. S, ROSENDORF, L. L, LEE, H. M, MISCHAK, R. P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Neoplasm - immunology Antineoplastic agents Biological and medical sciences Bone Marrow - drug effects Chemotherapy Female Humans Immunotoxins - adverse effects Immunotoxins - therapeutic use Male Medical sciences Melanoma - immunology Melanoma - therapy Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Ricin - therapeutic use Serum Albumin - analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!